PPT1 and hepatocellular carcinoma: Inhibition of PPT1 by Ezurpimtrostat has been shown to decrease hepatic tumor burden in a murine model of hepatocellular carcinoma by promoting lymphocyte infiltration into tumors in conjunction with anti-programmed death-1 (PD-1) therapy.